Key result
A single intra-articular micro-fragmented adipose tissue injection achieved the minimal clinically important difference for total WOMAC score in 56.7% of patients with hip OA at 6 and 12 months.
Why the study?
Micro-fragmented adipose tissue has been proposed as a promising option for hip osteoarthritis, but clinical outcomes required evaluation.
Does a single ultrasound-guided micro-fragmented adipose tissue injection improve clinical outcomes in patients with symptomatic hip osteoarthritis?
Observational (n=30)
Does a single ultrasound-guided micro-fragmented adipose tissue injection improve clinical outcomes in patients with symptomatic hip osteoarthritis?
A single ultrasound-guided intra-articular MFAT injection provides partial clinical benefit for hip osteoarthritis, with better outcomes observed in mild compared to moderate disease.
Purpose: Micro-fragmented adipose tissue (MFAT) has been proposed as a promising option for hip osteoarthritis (OA). The aim of this prospective study was to evaluate clinical outcomes of MFAT injections in patients with hip OA. Methods: Thirty patients (19 men and 11 women, 55.7 ± 8.2 years) with symptomatic hip OA (Tönnis Grade 1-2) were treated with a single ultrasound-guided MFAT injection. Patients were evaluated at baseline and 1-3-6-12 months of follow-up with the Visual Analogue Scale (VAS), Western Ontario and McMaster Universities Arthritis Index (WOMAC), and Harris Hip Score (HHS). Adverse events were also documented. MFAT samples were evaluated for cell analysis and characterization. The minimal clinically important difference (MCID) for the total WOMAC score was achieved in 56.7% of patients at 6 and 12 months. Better clinical improvement and MCID achievement were observed in mild compared to moderate hip OA. A total of 300.000 cells derived from MFAT produced small colonies from Day 10 (89.9 ± 61.2), increasing by Day 20 (129.9 ± 47.9). Conclusions: A single ultrasound-guided intra-articular MFAT injection represents a safe and promising option for hip OA treatment. However, the clinical benefit was partial, and better outcomes were observed in mild compared to moderate hip OA. Level of Evidence: Level IV.
No takes yet. Share an insight, caveat, or question.
Zaffagnini et al. (2025) conducted an observational in Hip osteoarthritis (n=30). Micro-fragmented adipose tissue (MFAT) was evaluated on Minimal clinically important difference (MCID) for the total WOMAC score at 6 and 12 months. A single intra-articular micro-fragmented adipose tissue injection achieved the minimal clinically important difference for total WOMAC score in 56.7% of patients with hip OA at 6 and 12 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: